Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 13,609 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed No phase listed Observational

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

NCT00888589
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Michael O'Connor
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Nov 3, 2026, 6:22 AM EST
Recruiting Phase 2 Interventional

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Hartford, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

NCT01431820
View directory record Official record
Conditions
Distal and Lateral Subungual Onychomycosis
Interventions
Luliconazole Solution, 10%, Vehicle Solution
Drug
Lead sponsor
Topica Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Nov 3, 2026, 6:22 AM EST
Completed No phase listed Observational

Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer

NCT02050620
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 2 Interventional Results available

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

NCT01636882
View directory record Official record
Conditions
Melanoma
Interventions
CVA21
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Park Ridge, Illinois • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Nov 3, 2026, 6:22 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Inflammatory Muscle Diseases

NCT05738824
View directory record Official record
Conditions
Inflammation In Skeletal Muscle
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional

Tailored Web-Based Intervention for Cancer Patients and Family Caregivers

NCT01415089
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
FOCUS-Web
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Human anti-TNF monoclonal antibody/adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Nov 3, 2026, 6:22 AM EST
Completed Early Phase 1 Interventional Results available

Melatonin Versus Placebo in Breast Cancer

NCT01805089
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin 3 mg
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

NCT05908240
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Conditions, Cardiovascular Diseases
Interventions
Care Coordinator Model
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 75 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT04915950
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

NCT00912574
View directory record Official record
Conditions
Melanoma
Interventions
GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51, Saline
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 2 Interventional

Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

NCT00006682
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, vinorelbine ditartrate
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional Results available

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

NCT02107482
View directory record Official record
Conditions
Psoriasis
Interventions
Levia Narrow Band UVB, Levia sham/visible-light source
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 1Phase 2 Interventional Results available

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

NCT00657618
View directory record Official record
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Nov 3, 2026, 6:22 AM EST
Recruiting Not applicable Interventional

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

NCT07701590
View directory record Official record
Conditions
Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions
Microlyte®, IP 1: Membrane Wrap - Hydro
Device
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 2 Interventional

GM-CSF as Adjuvant Therapy of Melanoma

NCT00350597
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Drug
Lead sponsor
Northern California Melanoma Center
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 3, 2026, 6:22 AM EST
Completed Phase 1 Interventional

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 3, 2026, 6:22 AM EST
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY3375968, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Recruiting Phase 1Phase 2 Interventional

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

NCT06502691
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions
Best Practice, Biopsy of Breast, Computed Tomography, Electronic Health Record Review, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Immune Checkpoint Inhibitor, Poly (ADP-Ribose) Polymerase Inhibitor, Positron Emission Tomography
Other · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 3, 2026, 6:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fractional Radiofrequency for Treatment of Acne Scars and Wrinkles

NCT05827510
View directory record Official record
Conditions
Acne, Wrinkle
Interventions
BTL-585F
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Davie, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Nov 3, 2026, 6:22 AM EST
Terminated Phase 2 Interventional Results available

A Study for Adults With Plaque Psoriasis

NCT01018810
View directory record Official record
Conditions
Psoriasis
Interventions
LY2525623 Intravenous, LY2525623 Subcutaneous, Placebo Intravenous, Placebo Subcutaneous
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mobile, Alabama • Peoria, Arizona • Hot Springs, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Nov 3, 2026, 6:22 AM EST